uracil has been researched along with Stroke in 6 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 9.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 9.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 5.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 5.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "Alogliptin did not increase the risk of either first or recurrent CV events when compared with placebo in patients with T2DM and recent acute coronary syndrome." | 2.87 | Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. ( Bergenstal, RM; Cannon, CP; Cavender, MA; Cushman, WC; Heller, S; Liu, Y; Massaro, JM; Mehta, CR; White, WB; Zannad, F, 2018) |
| "Early after an ACS, patients with type 2 diabetes mellitus experience a significant burden of HF events and recurrent ACS." | 2.87 | Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Liu, Y; Sharma, A; White, WB; Zannad, F, 2018) |
| "Alogliptin treatment recovered the reduction in occludin and ZO-1 induced by OGD/R." | 1.51 | The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. ( Guo, AH; Han, XF; Hao, FL; Lu, XJ; Wang, XL; Zhao, XF; Zhao, ZR, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Elharram, M | 1 |
| Sharma, A | 2 |
| White, W | 1 |
| Bakris, G | 1 |
| Rossignol, P | 1 |
| Mehta, C | 1 |
| Ferreira, JP | 1 |
| Zannad, F | 5 |
| Cavender, MA | 1 |
| White, WB | 4 |
| Liu, Y | 3 |
| Massaro, JM | 1 |
| Bergenstal, RM | 1 |
| Mehta, CR | 3 |
| Heller, S | 1 |
| Cushman, WC | 4 |
| Cannon, CP | 4 |
| Bakris, GL | 3 |
| Hao, FL | 1 |
| Han, XF | 1 |
| Wang, XL | 1 |
| Zhao, ZR | 1 |
| Guo, AH | 1 |
| Lu, XJ | 1 |
| Zhao, XF | 1 |
| Menon, V | 2 |
| Perez, AT | 1 |
| Fleck, PR | 1 |
| Kupfer, S | 2 |
| Wilson, C | 2 |
| Lam, H | 1 |
| Shimada, YJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
5 trials available for uracil and Stroke
| Article | Year |
|---|---|
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Topics: Acute Coronary Syndrome; Comorbidity; Diabetes Mellitus, Type 2; Evidence-Based Practice; Female; He | 2020 |
Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female | 2018 |
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double | 2018 |
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathie | 2015 |
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglyce | 2016 |
1 other study available for uracil and Stroke
| Article | Year |
|---|---|
The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells.
Topics: Animals; Brain; Brain Ischemia; Cells, Cultured; Endothelial Cells; Humans; Infarction, Middle Cereb | 2019 |